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ABSTRACT 
Trypanosoma brucei belongs to a group of parasitic protozoan called flagellates. It causes 
African sleeping sickness and is transmitted by tsetse fly of genus Glossina. African sleeping is a 
devastating vector-borne disease which threatens over 60 million people in 36 Sub-Saharan 
Africa. It causes over 70,000 deaths annually and is fatal unless treated. Reemergence of the 
disease in recent years has been a concern for scientists. There is concern on design of new drugs 
for the treatment of the disease because of the toxic effects of drugs designed around 50 years 
ago. 
Trypanosomes have great importance over the other parasitic organisms. They are able to 
synthesize phospholipids de novo. This makes the trypanosome phospholipid biosynthesis 
mechanism a very attractive target for design of new drugs. TbLpn which has been identified in 
T. brucei is a protein homo log to yeast and mammalian Lipins. Yeast and mammalian lipins are 
phosphatidate phosphatases involved in membrane biogenesis, energy metabolism and adipose 
tissue development. The lipin protein family in mammals and yeast catalyzes the 
dephosphorylation of phosphatidic acid to diacylglycerol, which is in tum used to synthesize 
phospholipids. Two conserved domains as well as the two aspartic acid residues necessary for 
enzymatic activity in lipin protein family have also been identified in TbLpn. This is a clear 
indication that TbLpn might represent functional homolog of lipin proteins. The goal of this 
research project is to demonstrate in vivo and in vitro enzymatic activity of TbLpn. Recombinant 
His-TbLpn expressed in Escherichia coli was purified over Nickel column and used to test the 
enzymatic activity of TbLpn. Native TbLpn was also immunoprecipitated from T. brucei 
cytosolic extract and used to carry out the dephosphorylation of phosphatidic acid. 
CHAPTER! 
INTRODUCTION 
1. Historical background of T. brucei and sleeping sickness 
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The history of Trypanosoma brucei and sleeping sickness is traced from the prehistoric 
period. Molecular Phylogenetic reconstruction based on the genes that code for small subunit of 
rRNA genes has been used to elucidate the evolution of trypanosome. The evolutionary tree 
(Figure 1) suggests an ancient split into two branches of trypanosomes. One branch contains all 
Salivarian trypanosomes and the other branch contains all the non-Salivarian lineages. Salivarian 
branch split into a clade containing trypanosomes that infect birds, reptiles, mammals, fish and 
amphibians. The salivarian trypanosomes (to which African trypanosomes belong) separated 
from other trypanosomes around 500 million years ago(24) 
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Figure 1: Multikingdom tree inferred from 16S-like rRNAs. The 16S-like rRNA sequences are aligned from 
divergent representative of the eubacteria, archaebacteria and Eukaryota. 
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The salivarian group is characterized by the presence of dense surface coat of proteins 
that is subject to antigenic variation. [10]. Most parasitologists strongly believe that the 
salivarian trypanosomes evolved to free living forms that were ingested by early invertebrates 
such as leeches and arthropods and became gut parasites around 380 million years ago. 
Mammals evolved around 180 million years ago and prototypes of tsetse flies appeared 130 
million years ago. When some insects become blood sucking, the trypanosomastids adapted to 
mammalian.hosts. Tsetse fly appeared some 35 million years ago and become the transmitters of 
trypanosomes [2.fil. Around 3 million years ago the climates of East Africa become drier and 
parts of the forests were changed to Savannah landscape. Consequently, prehominids moved 
from tropical rainforest for Savannah. The prehominids had to adapt to upright posture to be able 
to look over grass for predators, be able to run faster and also carry loads of food. They were 
exposed to bites by tsetse flies [2.[J. For a long time both tsetse flies and game animals coexisted 
in the same environment. This may explain why most Africa wildlife species are tolerant to 
trypanosomiasis. It is possible that trypanosomiasis played important role in early hominid 
evolution. This is because ancient and medieval history reveals that trypanosomiasis affected the 
lives of people living in sub-Sahara Africa at all times. Based on this assumption, only the 
trypanosome-resistant early terrestrial hominids were selected for survival. This is also evident 
from the observation that arboreal primates are susceptible to trypanosomiasis while humans are 
resistant [1J. 
The written evidence about the presence of trypanosomiasis in Africa during the middle 
ages is given by Arab traders who kept close trade relations with West Africa kingdoms such as 
Benin, Ghana, Mali, and Songhai. The famous Arabian geographer Abu Abdallah Yaqut (1179-
1229) gave an account of his journey to Africa. He found a village in Gold coast whose 
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inhabitants including their dogs were just "skin and bones and were asleep" (24). The report was 
indication of sleeping sickness epidemic which may be similar to the devastating sleeping 
sickness epidemic which occurred in Uganda in early 20th century. Trypanosomiasis influenced 
migration patterns of people in middle ages. People avoided regions infected by tsetse flies 
during the migrations [1, 24]. 
History of human African trypanosomiasis in early modem times is linked to slave trade. 
The ship doctors and medical officers who worked for slave trade companies were instructed to 
investigate on the disease which caused increasing losses to ship owners and slave traders. The 
first accurate medical report on African sleeping sickness was reported in 1734 by English naval 
surgeon John Aktins (1635-1757). The description of Aktins was based on neurological 
symptoms of the late stage of sleeping sickness. In 1803, Thomas Winterbottom (1766-1859) an 
English physician published a report referring to the characteristics signs of swollen lymph 
glands along the back of the neck in the early stage of the disease. His report mentioned that the 
symptom was known long ago by Arab slave traders who refrained from buying slaves with such 
sign[±. .M]. 
During the modem period, the major historical even was the discovery of tsetse fly­
trypanosome complex. The Scottish missionary and explorer David Livingstone ( 18 13-1875) 
first suggested that nagana is caused by the bite of tsetse fly (Figure 2). In 1852, he reported the 
presence of a disease in the valleys of the Limpopo ( in South Africa) and Zambezi rivers (In 
present day Mozambique) and also along the banks of lak�s Nyasa and Tanganyika both in 
present day Tanzania which killed all is cattle after they were bitten by tsetse flies. In 1895, 
David Bruce (1855-1931) who was a Scottish pathologist and microbiologist discovered T. 
brucei as the cause of cattle trypanosomiasis. In 1901, the British Colonial surgeon Robert 
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Michael Forde (1861-1948) made the first unequivocal trypanosomes observation in human 
blood when he was examining a steamboat captain in the Gambia. Robert Michael Forde first 
thought that the organisms he found were worms. A few months later, English physician Joseph 
Everett Dutton (1874-1905) identified the organisms as trypanosomes and proposed in 1902 the 
species name Trypanosoma gambiense (now T. b. gambiense). In the same year, the Italian 
physician and pathologist Aldo Castellani (1869-1971) found trypanosomes in the cerebrospinal 
fluid of sleeping sickness patient and suggested that they cause sleeping sickness. In 1903, Bruce 
provided conclusive evidence that sleeping sickness is transmitted by tsetse flies. He believed 
that trypanosomes were transmitted mechanically by tsetse flies. In 1909, the German military 
surgeon Friedrich Karl Kleine (1869-1951) showed the cyclical transmission of T. brucei in 
tsetse flies. The new development made Bruce change his original opinion of mechanical 
transmission of trypanosomes and described the full developmental cycle of the parasite within 
their insect host. Trypanosoma rhodesiense (now T. b. rhodesiense) which is a second human 
pathogenic trypanosome species was discovered in 1910 by two pathologists John William 
Watson Stephens (1865-1946) and Harold Benjamin Fantham (1876-1937) [1, 12, 24, m. 
Figure 2: David Livingstone exploration and discovery of tsetse tly-trypanosome complex. 
Limpopo is in South Africa below Zambezi. Other areas are ind icated in the map. 
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2. Geographical Distribution 
The genus Trypanosoma (Family: Trypanosomatidae; Order: Kinetoplastida) is comprised of 
unicellular flagellates that are parasites of all vertebrate classes. They cause African 
trypanosomiasis a disease also known as African sleeping sickness. The parasites are transmitted 
to mammals by the tsetse fly of the genus Glossina. The tsetse flies acquire the infection from 
humans or from animals harboring the pathogenic parasite [.1.2., 27]. The characteristic 
morphological forms of trypanosomes are the trypamastigotes which are observed in the blood 
and tissues of the vertebrate hosts, and the epimastigotes which are found in the invertebrate 
vector. For mammalian, avian and some amphibian and reptilian trypanosomes, the vectors can 
be haematophagous arthropods (insect or arachnids). In the cases of fish, certain amphibians and 
reptilian, the trypanosomes are transmitted by leeches [lQ]. 
Human trypanosomiasis is caused by two subspecies of T. brucei. The first subspecies is 
Trypanosoma brucei gambiense whose distribution is restricted to West and Central Africa. This 
parasite currently accounts for over 95% of the reported cases of sleeping sickness and causes a 
chronic infection. The parasite can infect a person for months or years without major signs or 
symptoms of the disease. The symptoms emerge when the patient is already in the advanced 
disease stage where the central nervous system is affected. T. b. gambiense is confined to human­
fly-human cycle [.[]. It is transmitted by the tsetse fly species Glossina palpalis [l.Q]. The second 
subspecies is Trypanosoma brucei rhodesiense. This subspecies is transmitted by Glossina 
morsitans species of tsetse fly and is found in Eastern and southern Africa UQ]. Currently, the 
parasite accounts for fewer than 5% of reported cases of sleeping sickness and cause an acute 
infection. The disease develops rapidly and invades the central nervous system. T. b. 
rhodesiense transmission to humans is influenced by prevalence of the parasite in the animal 
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reservoir. In East Africa, livestock are the important reservoirs for the disease. Control of animal 
infection and tsetse populations are important for reducing transmission to humans [fil.Untreated 
patients die within weeks or months after infection by either form of the parasite. The two 
protozoan species are morphologically indistinguishable but have drastic differences in 
epidemiological features. There is another form of trypanosomiasis called American 
trypanosomiasis or Chagas disease. It is mainly found in 21 Latin American countries and is 
caused by Trypanosoma cruzi [1, 12, H, W. 
Animal trypanosomiasis or nagana is caused by T. brucei subspecies called Trypanosoma 
brucei brucei. In animals, the parasite cause relatively mild infection while in domestic animals 
they cause severe and often fatal disease. The infection weakens the animal progressively until 
they become unfit for work, hence the name of the disease N' gana which is a Zulu word that 
means "powerless/useless". Animals also host the two human pathogenic parasites. For this 
reason, both domestic and wild animals can be important parasite reservoirs. The precise 
epidemiological role of the animal reservoir is not yet well known [1, 12, 21, 21]. 
The distribution of sleeping sickness in Africa corresponds to the range of region infected by 
tsetse flies. Currently the "fly belt" covers an area of 8 million km2 between 14 degrees North 
and 20 degrees South latitude [.MJ or from north of South Africa to South of Algeria, Libya and 
Egypt [.lfil. (Figure 3). The region includes 37 sub-Saharan countries with a population of 60 
million people. It is approximated that 500,000 are currently infected with the disease. 
Coo11 tnes reporting no cas.es 
Coontnes reporting under 100 Cll'!les 
• Counlnes rc,'PQ<1ing betv.'00" 100 3 1000 C<l:s.1.-'1; 
• C0UJ1tnes reporting more thal> 1000 cases { -
... , _______ _ 
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Figure 3: The dark l ine indicates the border which separated the type of parasite that causes sleeping sickness 
in different countries. The sleeping sickness in the eastern countries is caused by T b. rhodesiense whi le the 
sickness in the western countries is caused by T b. gambiense. The map also indicates the epidemic situation in each 
of the countries infested by tsetse flies. The three countries at risk of sleeping sickness epidemic are Sudan, 
Democratic Republic of Congo and Angola [:! ] 
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Despite the presence of tsetse fly in large areas within the 37 sub-Saharan countries, 
epidemics tend to occur in specific regions or foci. There are approximately 250 foci within the 
36 sub-Saharan countries [14]. The reason for this observation is that among the 31 species of 
Glossina, only 11 species transmit the disease to the human and are common in the specific 
regions where sleeping sickness is common [2ij. The main foci where sleeping sickness is 
common are indicated by black dots in Figure 4. 
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The specific foci where the epidemic occurs harbor the human-infective trypanosome 
strain which infects the humans. Such regions also have the right conditions that favor the 
presence of tsetse flies. Tsetse flies thrive well in environmental and climatic conditions which 
have humidity, shade and temperatures between 20 °C-30 °C [2[1.The regions have domestic and 
wild animals that are reservoirs for the parasites and interaction of the tsetse flies and people 
which promote infection. It has also been observed that the regions infected by tsetse flies are 
economically disadvantaged. The populations are in remote areas with limited access to adequate 
health services. This hampers surveillance and therefore the diagnosis and treatment of those 
infected [1, Q, 24, 27]. 
3. Life Cycle 
The entire life cycle of T. brucei occurs extracellularly (Figure 5). The human host is infected 
when the infective stage of the parasite called metacyclic is injected in by a tsetse fly. The 
parasite rapidly transforms into the long and slender blood stage called trypamastigotes. The 
trypamastigotes then divide by binary fission in the interstitial space at the site of the bite wound. 
In the human or the vertebrate host, trypanosomes depend entirely upon glucose for energy and 
are highly aerobic. Since the kinetoplast-mitochondria of the trypanosome completely lack 
cytochromes, the mitochondrion oxygen consumption is based on alternative oxidase that does 
not produce ATP. However, in the insect vector, the parasite develops conventional cytochromes 
chain and TCA cycle that uses ATP as source of energy [1, H]. The parasite in blood stage also 
expresses the variant surface glycoprotein (VSG). The VSG are family of glycoprotein that coat 
the trypanosome surface and are involved in host immune evasion. Any individual trypanosome 
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has single VSG expressed on their surface. At frequent intervals, a genetic switching event takes 
place that allows the VSG to be replaced by another family member with different antigenic 
characteristics. The genetic switching event of the VSG of the parasite is always one step ahead 
of the host immune response [lQ, .lII. The trypamastigotes then enters the blood stream through 
the lymphatic and divides further, increasing the amount of parasites in the blood. Some parasites 
transform into non-dividing short, stumpy form. These are biochemically similar to the long 
slender trypamastigotes, and infect tsetse fly when they ingest blood meal from infected host. In 
the insect vector, the short stumpy forms develop into procyclic trypamastigotes in the midgut of 
the fly. The procyclic form of the parasite shed the VSG coat and a new coat composed of 
procyclins is expressed (26). They continue to divide for around 10 days where they gain fully 
functional cytochromes system and TCA cycle. They migrate to salivary glands where they 
transform into epimastigotes. The epimastigotes divide and transform further into metacyclic 
trypanosomes that infect the human and reservoir host and the cycle is repeated as indicated in 
the Figure 5. 
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Figure 5: Life cycle of Trypanosoma brucei. 
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In the insect, the cycle takes about 25-50 days depending on the fly species, the parasite 
strain and the required temperature. There is possibility of genetic exchange between two strains 
in situations where the fly ingested more than one strain of trypanosome. This increases the 
genetic diversity in the organism. The tsetse lives for 2-3 months and can remain infected for the 
whole of their life. When taking blood meal, tsetse flies inject 40,000 metacyclic trypanosomes 
to organism. The minimum infective dose for most hosts is 300-500 metacyclic trypanosomes. 
Infection can also be acquired by eating raw meat from infected animals. The sucking arthropods 
can also mediate the transfer of trypanosomes by mechanical and inoculative means [1, lQJ. 
4. Three Major outbreaks and Disease Control 
Severe outbreak of sleeping sicknesss took place in some African countries during the 
late 19th century after the invasion of the interior of Africa by Europen explorers, missionaries, 
commercial agents, soldiers and colonial personnel. The conquest by the colonial powers meant 
unprecencedented biological, social and economic upheaval for the African countries. Africans 
were recruited as soldiers,forced labour introduced for construction of roads, railways, mining 
and collecting rubber. People were forced to move to unexplored environments. People were also 
pressed to move to tsetse infected lands to establish farms for cash crops which would raise 
enough taxes required by the colonial government. They were also relocated to new lands to 
create room for industrial expansion. These factors exposed people to bites by tsetse flies. Forced 
labor and new means of transport by roads and railways made movement of people more 
frequently and transmission of trypanosome strains from one place to another become possible. 
The result of exposure of people to bites by tsetse flies and transmission due to frequent 
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movement of people lead to the first recorded major epidmic of sleeping sickness which took 
place in Uganda and Congo (Present Democratic republic of Congo) between 1869 and 1906. 
The epidemic caused approximately 500,000 deaths in Congo Basin and 300,000 in Busoga 
focus in Uganda and Kenya [24, m. The second epidemic of sleeping sickness took place in 
1920. This was a small epidemic of sleeping sickness that spread throughout West Africa from 
Senegal to Cameroon. This second epidemic also included spread of sleeping sickness to the 
present day Democratic Republic of Congo. Colonization factors were responsible for the 
outbreak of the second epidemic. The third sleeping sickness epidemic occurred in Uganda in 
1940-1946. Uganda has suitable environment for habitation of tsetse flies because of the Rift 
Valley that transect the country and provide required conditions for habitation by tsetse flies. 
Uganda is also more susceptible to sleeping sickness epidemic because it has foci of both forms 
of sleeping sickness [1_, 12, 21.,. m. These two favorable conditions lead to the 1940's epidemic. 
This period also coincides with World War 11 which may have also contributed to the epidemic. 
To control the spread of sleeping sickness, the colonial administration used several 
methods. The first method used was separating patients into sleeping sickness centers. This 
included evacuation of people from areas heavily infected with tsetse flies to break the contact of 
people with the flies. This was practiced in Uganda and Tanzania by evacuating the whole 
population to 3 to 5 km from the water front shores of Lake Victoria. This was completed in 
1907 and reduced the number of patients from 30,000 in 1905 to 1,500 in 1907 in Uganda. 
Though this was a practical emergency solution, the uninhibited areas offered ideal place for 
game and tsetse to regenerate and resulted to large expansion of tsetse infected zones. The 
second control method was introduced in 1910 and involved use of differently designed targets 
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and traps. The traps were placed in the regions commonly infested by tsetse flies to attract them. 
(Figure 6) 
23 
Figure 6: Trap for eradication of tsetse flies 
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Tsetse flies are attracted to traps and targets by their host-seeking behavior, visual and 
olfactory stimulation. With the development of potent attractants in the last 20 years and the 
production of second-generation synthetic pyrethroid insecticides, this form of control technique 
has become highly successful. Traps and targets are placed in and around areas where human-fly 
contacts are greatest such as streams frequented by villagers and fridges of cultivated fields. The 
traps and targets contain insecticides that kill the tsetse flies and others kill the tsetse flies 
through tapping mechanism. This method was successfully used in Kenya to suppress tsetse fly 
population. The method was popular before the introduction of chemical control during Second 
World War. Bush-clearing, which is the third control method used, exploited the knowledge that 
tsetse flies concentrate in certain areas. This approach was successfully used in West and East 
Africa to drastically make the areas unsuitable for tsetse fly habitation. Although the method is 
apparently successful, it is unsuitable because the tsetse flies reinvent other region. The method 
is also expensive and has adverse effect on the environment due to destruction of vegetation [�, 
21, m. The reservoir host control and game destruction is the fourth control method and was 
recommended by Bruce. It was practiced in Zimbabwe, Uganda and Southern Sudan between 
1920 and 1940. It resulted in significant decline of tsetse fly population, but never reached the 
point of extermination of the tsetse flies [2.QJ. The method involves hunting to reduce the 
reservoir hosts. Chemicals are also used to control population of tsetse flies. The method was 
introduced in 1949 after the introduction of the insecticide DDT during the Second World War 
and took over from traps and hand catching of tsetse flies. It was largely used in East Africa from 
1950's to early 1970's. Residual insecticides such as organochlorine, pyrethroids, and 
avermectins are spread to areas where human-to-fly contacts are likely. The chemicals are spread 
from the ground or from the air. Pyrethroids are preferred because they are rapidly degraded in 
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soil and are environmentally safe. Organochlorine and carbamates bioaccumulate in food chain 
and are highly toxic to mammals and other vertebrates. They have been banned for widespread 
outdoor spraying. Ground spraying using manual pressurized knapsacks has been successfully 
used to reduce the population of tsetse flies in West Africa [1_, 24, 2.8.). The principle of 
systematic case detection and treatment using mobile teams was introduced by French military 
surgeon Eugene Jamot (1879-1937). It involved systematic case detection and treatment. The 
aim of the mobile teams was to eliminate parasite reservoirs and was applied in Cameroon. By 
the use of this method the prevalence level of sleeping sickness declined from 60% in 1919 to 
0.2-4.1 % in 1930. The method was also introduced by British, Belgian and Portuguese in Ghana, 
Nigeria, Cameroon, Congo DR and Angola. By late 1960's the overall percentage of new T. b. 
gambiense cases had fallen to below 0.01 %. Another modem method of disease control is Sterile 
Insect Technique which was considered as a means to control tsetse fly control by Simpson in 
1958. It involves mating wild females with sterile male flies. Under the normal physiological 
circumstances, female tsetse flies are only required to mate once to store sperms in its 
spermathecae in sufficient quantity such that fertilization can occur over its entire reproductive 
life. Mating with a sterile make would therefore result in no offspring. This method was 
considered to be impractical for control of high-density tsetse fly population because large 
number of sterilized male would be required. For this method to be effective, it has been 
estimated that 10% of females in the population need to be inseminated. This requires 80% of 
sterilized male to be released in the population [fl. However, the sterile male technique was 
successfully used in the Island of Zanzibar to eradicate tsetse flies and thus trypanosomiasis in 
1997. The method worked successfully in Zanzibar because it is an isolated island which was 
only infested with only one tsetse fly species (62]. 
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During the colonial period, there were constant screening and surveillance measures 
against possible outbreak of the disease in all the countries which are exposed to possible 
epidemic outbreak. As a result there was decline in cases of sleeping sickness in all the 
trypanosomiasis-endemic countries. The colonial period in most of Africa countries ended in 
early 1960's. The figure 7 below shows the decline of sleeping sickness to very low levels in 
1960's. 
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Figure 7: This figure shows the number of newly registered cases of human African trypanosom iasis in past 75 
years according to WHO [25]. It has indication of the re-emergence of the disease after the great decline in I 960's. 
5. Re-emergence of sleeping sickness epidemic 
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Sleeping sickness has re-emerged in many African countries since the 1970's . The re­
emergence of the disease has been attributed to post-independent political turbulence, unstable 
governments, limited public health resources and, relocation of domestic and international 
funding towards malaria, IDV I AIDs and tuberculosis. The figure 7 indicates the gradual re­
emergence of the disease since 1970,s. The political turbulence and unstable government include 
occurrence of civil war, rebel insurgency, violent governance, political or military oppression of 
populations and military combat. The re-emergence of the outbreak of sleeping sickness since 
1970's has been observed in sub-Saharan countries including Democratic Republic of Congo, 
Sudan, Angola and Uganda. The countries were associated with political instability after 
independent and especially during the periods of specific epidemic in each particular country [fil. 
Political instability is associated with collapse of health services, veterinary and vector control 
measures. There was also reduction in surveillance and treatment of those infected by the disease 
rn_, 12, 24]. The first post-independent epidemic of sleeping sickness was experienced in 
Uganda. The epidemic of T. b. rhodesiense began in south east of the country between 1976 and 
declined in mid-1990. This period coincides with political instability and civil wars during and 
after the rule of Idi Amin. The civil war influenced the transmission of sleeping sickness in a 
number of ways including breakdown of veterinary and public health services, collapse of vector 
control, regrowth of bushy tsetse habitat in abandoned agricultural fields, increased 
displacements of animal and human populations into marginal or swampy areas where they were 
more likely to be bitten by the flies. During the period of the epidemic, over 40,000 cases were 
reported. It has been hypothesized that the actual cases may have been ten time higher due to 
unreported and untreated cases. Though the decline in 1990's, the disease continues to spread in 
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other areas. The presence of the two types of trypanosomiasis in Uganda complicates control 
efforts [1, �,]. Similar re-emergence of sleeping sickness was experienced in Angola during the 
prolonged civil war following the country's independence in 1975. The political situation of 
Angola has remained highly unstable even after the signing of peace agreement in 2002. The 
infrastructure is collapsed and the country is classified by World Health Organization as 
"epidemic" for sleeping sickness together with Democratic Republic of Congo and Southern 
Sudan. In Sudan, the disease re-emerged fa 1970,s but was immediately controlled by Belgian­
Sudanese trypanosomiasis treatment and control initiative. The control program collapsed in 
1980s and 1990's due to civil war. As a result, the sickness re-emerged again in 1997 with 
prevalence rate of as high as 19% in south-western communities that border DRC. In the 
Democratic Republic of Congo, the outbreak of sleeping sickness re-emerged in 1970, and 
1980's. The country has the highest burden of the disease in Africa In 1994, 72% prevalence 
was reported in one village. According to WHO, Angola and southern Sudan have also reported 
high prevalence of between 20% and 50% in some communities. Sleeping sickness in some of 
the communities is the first or the second cause of mortality ahead of HIV/AIDs [H, 12, 2.fil. 
It is important to mention that the people exposed to tsetse flies and therefore to possible 
infections are in rural populations and depend on agriculture, fishing and animal husbandry or 
hunting. These people are economically affected because of limited resources for medical 
treatment and also death of their livestock wbjch are basic source of meat and milk [28]. Such 
remote regions are not accessible due to poor infrastructures. 
At the turn of the century, the sleeping sickness infection had almost reached the level of 
epidemic witnessed at the beginning of the century. The situation got even worse because the 
production of Eflornithine was stopped and there was threat to discontinue the supply of 
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Melarsoprol. In 2001, WHO reached an agreement for supply of drugs for sleeping sickness free 
of charge in endemic countries. Surveillance was reinforced in 2005 and the number of cases 
reported on the continent has reduced. The number of both forms of the disease fell from 37,199 
to 17,616 between 1998 and 2004. The estimated number of actual cases was between 50,000 to 
70,000. Due to continued control efforts, the number of reported cases has dropped to 10,000 in 
2009. This is the first major drop in the number of cases in 50 years. By 2010 the estimated 
actual number of cases was 30,000 (12, 24, 27]. The figure 8 below shows the number of 
reported cases of sleeping sickness and the population that was screened during 1939-2004. 
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Figure 8: The columns indicate the number of reported cases and the black l ine represents the population 
screened. 
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Currently the prevalence of the disease differs from one country to another as well as in 
different parts of the same country. The Democratic Republic of Congo reported over 70% cases 
in the last 10 years. In 2008 and 2009, only DRC and Central Africa reported over 1,000 cases 
per year. During the same period, countries like Angola, Chad, Sudan and Uganda reported 
between 100 and 1,000 new cases per year. 
6. Stages and symptoms of the disease 
Sleeping sickness is characterized by two distinct phases which are the early and the late 
phase. The early phase is called hemolymphatic. In this phase, the trypanosomes are restricted to 
blood and lymph system. The symptoms of this phase include fever, headache, hardened chancre 
at site of bite, red rash at site of bite, weight loss, and swelling of lymph nodes. The second 
phase is called neurological phase. In this stage, the trypanosomes cross the blood-brain barrier 
through a mechanism which has not been determined and are found in neural tissue and 
cerebrospinal fluid. The symptoms during this phase include confusion, disturbed sleep pattern, 
increased muscle rigidity, tremors, speech disorders, stupor, seizures, and irritability. Unless 
treated, sleeping sickness patients die within months after infection [.U, H, �. 2-1, �. 
7. Treatment 
The colonial administration was so worried by the disastrous effect of sleeping sickness 
epidemic of the early 20th century that they sent out scientific missions to investigate the disease 
and develop cure. The scientific mission and combined efforts of chemists and pharmaceutical 
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companies developed drugs for treatment of sleeping sickness. One of the drugs developed for 
phase 1 of the disease is Suramin which was discovered in 1921. It is used for treatment of T. b. 
rhodesiense. Although the mechanism of action of Suramin is unknown, it is believed that it has 
a pleotropic effect. The side effects of the drug are infection of urinary tract and allergic 
reactions as well as fever, polymeurophathy, hematological toxicity and renal failure. 
Another drug for phase 1 of sleeping sickness is Pentamidine. It was discovered in 1941. It 
is used for the treatment of T. b. gambiense. Recent evidence show that Pentamidine binds and 
interferes with the parasite nucleic acid. It has some undesirable effects, but is well tolerated by 
patients [ 12, 24, 27]. Several drugs for the treatment of phase 11  of sleeping sickness have been 
designed. Melarsoprol was discovered in 1949. It is the drug of choice for treatment of both T. b. 
rhodesiense and T. b. gambiense. The drug is derived from arsenic and although effective, carries 
several important side effects; It induces reactive encephalopathy in 10% of the patients treated 
and is fatal in half of those instances. There has been resistance to the drug by patients especially 
in several foci particularly in central Africa [.12., 14, 24, ll]. The toxic effect of the drug is the 
main concern for its use in the treatment of sleeping sickness. Eflornithine molecule is less toxic 
than Melarsoprol. It was registered in 1990 and is only effective against T. b. gambiense. It is an 
irreversible inhibitor of ornithine decaboxylase and acts by blocking polyamine synthesis. The 
combination of Nifurtimox and Eflornithine drugs for treatment of phase 11 of sleeping sickness 
was introduced in 2009. Nifurtimox is registered for the treatment of American trypanosomiasis 
but not African sleeping sickness. Its combined use with Eflornithine has been accepted for 
treatment of African sleeping sickness and listed by World Health Organization as essential 
medicine [.12., 24, m. There are some challenges to the efforts to treat sleeping sickness. The 
efforts to design vaccine for sleeping sickness have been thwarted by the ability of the 
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trypanosomes to undergo antigenic variation as mentioned earlier. Trypanosomes have over 
1,000 possible surface coats and many more are generated by recombination. The tolerance of 
the parasite to drug treatment is also a great challenge. Another challenge to treatment of 
sleeping sickness is associated with socioeconomic realities in the specific regions of infection. 
The regions lack adequate resources, surveillance measures and infrastructures to control the 
disease. As it was mentioned earlier, the toxic effect especially of the arsenic derivative drugs 
remains a great challenge [12, 14, 24]. Another difficult is associated with diagnosis of the 
sickness. The diagnosis requires high degree of training and expertise. The parasite has to be 
detected. The detection of the parasite relies on conventional techniques such as lymph node 
puncture, blood film examination or other methods to concentrate parasites in the blood. The 
concentration of trypanosomes in the blood undulates below detection level especially in West 
Africa trypanosomiasis. This is a major parasite detection challenge for exaniinations may have 
to be repeated daily [2ij. 
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Figure 9: Drugs currently in use for the treatment of human sleeping sickness. 
35 
36 
8. VSG and Antigenic Variation 
As briefly mentioned earlier, Antigenic variation in African trypanosomes is a 
mechanism for evasion of the host's immune response. The complex mechanism arose in the 
course of evolution of the genus Trypanosoma and it is difficult to approach experimentally. The 
genes that code for the variant surface proteins ( vsg genes) code for the coat that cover the 
parasite. There is extensive variability of this large gene family both within a species and 
between species that are known to undergo antigenic variation. There are over 1,000 possible vsg 
genes and many more are generated by recombination mechanism. In a given cell and at a given 
time, only one of the genes is expressed. Trypanosome clones form antigenically different VSG 
coats by the differential activation of previously inactive vsg gene and the parasite is always one 
step ahead of the host's immune response. This makes possibility of generating a universal 
vaccine against human sleeping sickness seems remote. The need for other control strategies is 
paramount to control the disease [.l.Q, 111-
9. Lipin Protein Family 
The protein family of lipins has been described in many organisms including mammals, 
yeast, plant and protozoa [ll, 12.J. Lipin proteins have several cellular functions (Figure 10). 
First, they serve as enzymes required for triacylglycerol (TAG) and phospholipid biosynthesis. 
Secondly, they also serve as transcriptional coactivator in regulation of lipid metabolism genes. 
Since one of the major constituents of biological membranes is phospholipids, lipin plays vital 
roles in membrane biogenesis [19, 2_1]. TAG plays a vital role in metabolic homeostasis. It serves 
as the major energy storage molecule that allows organisms to survive period of food 
deprivation. The regulation of TAG is important in human disease. This is because both 
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excessive and inadequate fat storage is associated with dyslipidemia, insulin resistance and 
diabetes [2_] 
Lipid Biosynthesis Transcriptional coactiva tor 
Phosphatidic acid Lip in 
Diacylglycerol 
Phospholipids Triacylglycerol l 
Gene Transcription 
Figure 10: Functions oflipin protein family. Mammalian and yeast lipins are involved in 
Lipid biosynthesis as well as having an essential role in phospholipid gene transcription. 
HAT: Histone acetyltransferase; PGC-1: Peroxisome proliferator-activated receptor gamma 
coactivator 1-a 
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The founding member of lipin protein family is lipin- 1. It was identified in 2001 through 
positional cloning of mutant gene that is responsible for fatty liver dystrophy (jld) mouse .Fld is 
a genetic disease characterized by loss of body fat, fatty liver, hypertriglyceridemia and insulin 
resistance. The fld mouse is deficient for lipin-1 due to null mutation of the Lpinl gene [.�, _l2, 
m. 
Three different lipin proteins have been identified in mammals. These include the two 
lipin-1 isoforms that are generated by alternative mRNA splicing of Lpin l gene giving rise to a 
protein with predicted sizes of approximately 98 and 102 kDa (Figure 1 1) 
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Figure 1 1 :  Lipin in mammals 
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The other two lipin proteins are lipin-2 and lipin-3 . They were identified through similar 
sequences which were used to identify lipin-1 .  The three mammalian lipin genes are expressed 
differently in different tissues as indicated in Figure 1 1 . The different expression suggests that, 
each lipin gene has unique physiological roles in the tissue where it is expressed. Lipin-1 is 
highly expressed in white and brown adipose tissue, skeletal muscles and testis. It is also 
detectable in liver, peripheral nerve, brain, kidney and pancreatic beta cells. Lipin-2 is 
prominently expressed in liver and brain. Lipin-3 is expressed at low levels in several tissues 
including small intestine and liver [�, 11, 12., £1). At present, little is known about the 
physiological role of lipin-2 and lipin-3 . However, mutation of lipin-2 gene LPIN2 was identified 
in Majeed syndrome. This is a disorder characterized by congenital dyserythropoetic anemia, 
recurrent fever, chronic recurrent osteomyelitis and cutaneous inflammation. Since lipin-3 is 
expressed in the stomach and intestines, it may play a role in absorption of dietary fat [ill . 
Orthologs of two Lpin-1 related genes, Lpin2 and Lpin3 have been identified in 
Schyzosaccharomyces pombe, Saccharomyces cerevisiae, Drosophila melanogaster, 
Caenorhabditis elegans, Arabidopsis thaliana and Plasmodiumfalciparum [2, 1.2,. 2 1] .  
The lipin proteins in nearly all species posses nuclear localization signals, as well as 
several putative and serine and threonine phosphorylation sites. In addition, all lipin proteins 
share extended regions at the amino terminal lipin (N-LIP) and carboxy-terminal lipin (C-LIP) 
domains that are highly conserved. The highly conserved domains suggest an important 
functional role of these domains. The C-LIP domain contains the haloacid dehalogenase (HAD) 
catalytic site which is required for enzymatic activity [ll, 19, 2 1] .  
N-LIP C-LIP 
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Figure 1 2: Conserved domains found in l ipin proteins. S I  06: conserved serine residue 
(position I 06 in Lipin- 1 ); NLS: nuclear localization sequence; DxDxT: phosphatidic acid 
phosphatase active site; Lxx lL :  transcription factor interaction domain . 
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As described above, two distinct cellular functions of Lipin-1 have been identified. They 
serve as enzyme in TAG and phospholipid biosynthesis. The second role is that they act as 
transcriptional coactivator that regulates expression of fatty acid utilization and lipid synthetic 
genes (Figure 10). PAP mammalian homologue of lipin catalyzes the dephosphorylation of 
phosphatidic acid (PA) to yield diacylglycerol (DAG) and inorganic phosphate. With the 
identification of a gene that code for P APl enzyme, it has been shown that the enzyme has a role 
in de nova lipid synthesis. The DAG produced through catalytic activity of PAPI is used for the 
synthesis of membrane phospholipids phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE)( Fig. 13). [2, �. 1.2, 21]. 
Regulation of lipin-1 is complex. It takes place at the level of mRNA transcription, 
mRNA splicing, protein phosphorylation and subcellular localization. Although most TAG 
biosynthesis enzymes reside in ER or mitochondria, P APl is primarily cytosolic and translocates 
to the ER membrane in response to fatty acids or acyl-CoAs. 
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Figure 13: Role of PAP in lipid synthesis and signalling in yeast. 
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At its translocation to ER the PAPI converts phosphatidic acid to DAG which in turn is 
used for the synthesis of PE and PC as mentioned earlier. In the liver, PAPI activity is increased 
in diabetes, hypoxia and toxic fatty liver. The PAPI activity is also increased in response to 
elevated glucocorticoids. In adipose tissue, PAP is decreased in starvation and diabetes to reduce 
TAG synthesis and increase lipolysis. Thus there are important differences in regulation of PAPI 
activity in specific tissues. PAPI is also regulated by phosphorylation. There are multiple sites 
that have been identified in lipin-1 that are phosphorylated in response to insulin [l.2, 2 1 ] .  
In yeast, P AHl has been identified as the lipin ortholog. The P ARI was shown to possess 
the same Mg+-dependent PAPI activity. The catalytic activity is conserved in all lipin related 
proteins of different organisms from mammals to yeast and is mapped to the DxDxT motif which 
is present in the C-LIP domain. The first aspartic residue in the DxDxT catalytic motif acts as a 
nucleophile that forms an aspartyl-intermediate during catalysis. The second aspartate residue 
binds and protonates the substrate leaving group in the first step, and deprotonates the 
nucleophile of the second step. The cofactor Mg+ is coordinated by the carboxylate group of the 
first aspartate and the backbone of the second aspartate. Since aspartate residues are required for 
catalytic activity, mutation of the first aspartate within the DxDxT motif abolishes PAPI activity 
of lipin- l [;i, 198, 2 I ] . The yeast PAHlP, which is the mutant PAHI, leads to substantial increase 
in PA levels accompanied by decrease in TAG and DAG. The levels of phosphatidylinositol, PE 
and PC are also affected [11 1.2]. 
As indicated above, lipin-I is highly expressed in adipose tissue, skeletal muscles, testis 
and is also detected in liver, heart, brain, kidneys and other tissues. The deficiency of lipin-I 
results to immature adipocytes those are unable to store lipids or express mature adipocyte 
markers. The result of the deficiency is loss of body weight, peripheral neuropathy due to myelin 
46 
degradation, Schwann cell differentiation defects and proliferation and nerve conduction 
velocity. 
In transgenic mice, enhanced lipin-1 expression promotes obesity. This is because of high 
TAG stored in the adipose tissues and skeletal muscles [2, 19, 20, 21]. It is important to mention 
that the most abundant phospholipids in eukaryotic cells are PC and PE. PC accounts for 30-50% 
of the total phospholipids while PE accounts for 40% of the total phospholipids ll.2] . 
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Figure 1 4: Obese mouse, the result of lpn-1 gene overexpression 
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10. Trypanosoma brucei lipin (TbLpn) 
T. brucei has become a model organism to study general biological processes such as 
RNA editing, Glycoslyphosphatidylinositol (GPI) anchoring, trans-splicing and antigen 
variation. These biological phenomena were initially discovered in trypanosomes and later 
observed in other organisms. New studies have also demonstrated that the differentiation of T. 
brucei from bloodstream form to procyclic form of the parasites may reveal changes in gene 
expression and metabolism that are essential for the parasite life cycle. Recent series of reports 
have also demonstrated that both blood stream and insect form parasite are capable of de novo 
synthesis of all major phospholipids. It has long been known that T. brucei bloodstream forms 
acquire lipids from their mammalian hosts. The new report has raised new interest in T. brucei as 
a model organism to study eukaryotic lipid homeostasis. The de novo phospholipid biosynthesis 
by trypanosomes has become very attractive target for design of new drugs. The main 
biosynthesis pathways for phospholipids synthesis in T. brucei have been determined [ 1 9, 2 1 ]  
TbLpn is the protein homolog to yeast and human lipin. To understand how TbLpn was 
discovered, it is important to describe protein arginine methylation. Arginine methylation is 
modification of protein after translation. Arginine methylation involves addition of methyl 
groups from S-adenosylmethionine (AdoMet) to nitrogen of arginine residue in proteins. 
Arginine methylation is catalyzed by enzymes called protein arginine Methyltransferases 
(PRMTs). PRMTs have been discovered in many organisms including mammals, yeast, plants 
and protozoa [l] . The role of arginine methylation has been established recently as control of 
signal transduction, RNA transport, RNA processing, protein localization and transcription. 
Currently, the functional significance of many arginine methylation events is unknown. Two 
major and distinct types of PRMTs have been identified in mammalian cells. Type 1 enzyme 
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catalyzes the formation of both monomethylarginine (MMA) and asymmetrical dimethylarginine 
(ADMA). The type 11 enzyme forms MMA and symmetrical dimethylarginine (SDMA) �]. 
(Fig.11) 18 
To understand the function of arginine methylation in Trypanosoma gene expression and 
to identify the substrates and/or regulators of PRMTs in T. brucei, proteins interacting with the 
major type 1 PRMT were identified using the yeast-two-hybrid screening procedure. Several 
TbPRMT l interacting proteins were identified, one of which being homologous to yeast and 
human lipin. The gene encodes a protein, termed TbLpn with predicted 806 amino acid residues. 
The protein is predicted to have a molecular weight of 86.7kDa and ·a pl of 4.9. The predicted 
protein is 15% identity to human lipin and 25% identical to yeast smp2 at the amino acid level. 
The 15% and 25% identity is reasonable because the trypanosomes diverged from other 
eukaryotes very early during the process of evolution [23]. It has been determined that the TbLpn 
contains the two conserved domains N-LIP and C-LIP which is characteristic of lipin protein 
family. Most importantly, the predicted amino acid sequence of TbLpn have the presence of 
DxDxT motif namely DVDGT which is located from amino acid 445 to 449. The conserved 
domain has the aspartic acid residues which have the enzymatic activity of the protein (Fig. 15). 
This is a clear suggestion that TbLpn possess PAPI activity which is the characteristics of other 
lipin protein family members [�] 
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The goal of the research project is identify the enzymatic activity of TbLpn both in vitro 
and in vivo. Since TbLpn share all the characteristics of lipin protein family, it is hypothesized 
that it should display similar enzymatic activjty. 
The current research is significant. It will be important to know that TbLpn has a 
phosphatidic acid phosphotase activity. T. brucei synthesizes two major phospholipids namely 
phosphatidylcholine (PC) and phosphatidylethanolamine (PE). The PE is a precursor to 
glycosylphosphatidylinositol (GPI) synthesis, a molecule that anchors VSG in the cell 
membrane. The PAP activity may also be involved in the membrane rearrangement during 
differentiation from bloodstream to procyclic parasite. The differentiation is marked by shedding 
of VSG coat and expression of new coat composed of procyclins, which are in two major classes 
namely GPEET and EP (2Q). 
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CHAPTER 2 
MATERIALS AND METHODS 
1. Production of recombinant TbLpn 
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C-terminally his-tagged ThLpn was generated as follows. Total Procyclic form cDNA 
was generated by reverse transcription primed with [dT]-RXS. The entire ThLpn ORF was 
amplified using Deep Vent DNA polymerase (New England Biolabs), and using oligonucleotides 
hisl O-lipin-5' (5'-CGGGATCCATGGTGATCCGACCTGCAAC-3 ') and His10-lipin3 ' (5 '­
CCCAAGCTICCGCTCGAGTTACAACACAA TGGGATGATCCG-3 ') (restriction sites are 
underlined) which were constructed based on the genomic sequence. The PCR product was then 
digested with BamHI and Xhol, ligated into the pET26-His10Smt3 expression vector, giving rise 
to pHisl O-ThLpn, and transformed into E. coli BL21 competent cells (Invitrogen). 
Protein expression (1 liter of cells) was induced with 1 mM isopropyl P­
thiogalactopyranoside (IPTG) and 2% ethanol for 17 h at 17 °C. Cells were harvested by 
centrifugation at 4,000 RPM (rotation per minute) for 10 min at 4 °C. The cell pellet was 
resuspended in 50 ml of lysis buffer (10 mM Tris [pH 8.6], 10 mM glycine, 300 mM NaCl, 10 
mM imidazole, 10% glycerol, 10% ethanol, 4% Tween-20, and 3% Triton X-100) containing 
0.05 mg/ml lysozyme, 0 .0 1  mg/ml DNase I, 1 mM phenylmethylsulfonyl fluoride (PMSF), 
l µg/ml leupeptin, and l µg/ml pestatin A. The cells were then lysed by 3 freeze/thaw cycles. 
Each cycle consisted of incubation at 37 °c for 15 minutes, followed by incubation at -80 °c for 
another 15 minutes. The lysate was centrifuged at 17,000 X g for 15 minutes. The lysate which 
contained the ThLpn was stored in freezer for the next procedure while the cell debris was 
discarded. 
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Following thawing, the cell lysate was mixed with Probond Ni2+ resin (Invitrogen) and 
rotated for 4 hours at 4 °C. The mixture was poured into a column, and the flowthrough collected 
and stored at -20 °C. The column was washed with 50 ml Tris buffer (pH 7.0) containing 200 
mM NaCl and 30 mM imidazole in the presence of 1 mM PMSF, 1 µg/ml Leupeptin, and 1 
µg/ml Pestatin A. The wash was collected as 1 fraction and stored in freezer. Purified hisl O-
ThLpn was eluted with 10 ml of Tris buffer (pH 6.0) containing 200 mM NaCl and 300 mM 
imidazole in the presence of 1 mM PMSF, 1 µg/ml Leupeptin, and 1 µg/ml Pestatin A. The elute 
was collected in 10-1 ml fractions and stored in freezer for the next procedure. 
2. Analysis of column fractions 
The flowthrough, wash, and elution fractions were analyzed by denaturing 
polyacrylamide gel electrophoresis (SDS-PAGE). Ten µl of the flowthrough, 20 µl of the wash, 
as well as 20 µl of elution fractions 1,2, 3, 4, 6, 8, andlO were mixed with the appropriate 
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volume of 5X denaturation buffer (SOS) and denatured at 100 °C for 5 min. The samples were 
then loaded onto a 7.5% acrylamide SOS-PAGE separating gel (separating gel buffer) with a 4% 
acrylamide stacking gel (stacking gel buffer). The gel was run at 200V in denaturing running 
buffer (25 mM Tris, 0 .1% SOS, 192 mM glycine). Proteins were stained with Coomassie Blue. 
3. Western hybridization 
Following electrophoresis, proteins were transferred to a polyvinylidene fluoride (PVOF) 
membrane at 50 V for 45 min in 10 mM 3-[Cyclohexylamino]-1-propanesulfonic acid (CAPS) 
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buffer (pH 11 .0) containing 10% methanol. The membrane was first soaked in 1 xTBS for 10 
minutes. This was followed by incubation in 10% dry milk in 1 xTBS for 20 hours. After the 
incubation for 20 hours, the membrane was rinsed twice in 1 x TBS-T for five minutes each rinse. 
This was followed by incubation in 2% dry milk in I x  TBS-T containing primary antibody (anti­
His monoclonal antibody, 10µ1, 1 :  2000) for 20 hours. This was followed by rinsing the 
membrane three times with 1 xTBS-T for 15 minutes each rinse. The membrane was then 
incubated in secondary antibody (Goat anti-mouse antibodies conjugated to horseradish 
peroxidase, 1 :  I 0,000) in 2% dry milk in 1 xTBS-T for 1 hour at room temperature. This was 
followed by rinsing the membrane three times for 15 minutes each rinse in 1 xTBS-T after which 
it was incubated in developing solution for 5 minutes at room temperature. Reactive proteins 
were detected using enhanced chemiluminescence (GE Healthcare). 
4. Protein concentration 
The protein fractions were concentrated using a 20K (MWCO) concentration tubes 
(ThermoFisher Scientific). Samples were centrifuged at 2500 X RPM (rounds per minute) for 60 
minutes. The elutes were discarded, and the tubes filled with TE buffer and centrifuged at 2500 
X RPM (rounds per minute) for 60 minutes. The elutes were discarded and the procedure 
repeated once more. Concentrated samples were collected in 5 fractions each fraction containing 
50 µl, and stored at -80°c. 
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5. Expression of a his-TbLpn (DEAD) mutant 
A mutant version of TbLpn, in which the two conserved aspartic acid residues in the 
DVDGT motif (445D, 447D) are changed to alanine, was generated by PCR amplification from 
pHislO-TbLpn using the QuikChange II XL™ Site-Directed Mutagenesis Kit (Agilent 
Technologies) and the mutagenic pnmers TbLpn-DEAD-5' (5 '­
CTTGTCATTAGTGAAGTGGAAGGCACGATCACGAAAAG-3 ') and TbLpn-DEAD-3' (5'­
CTTTTCGTGATCGTGCCTTCCACTTCACTAATGACAAG-3'). The 50 µl reaction contained 
100 ng of pHislO-TbLpn DNA template, 2.5 units of Pfu Ultra DNA polymerase, 2 µl of 
deoxyribonucleotide tryphosphate mix, and the two mutagenic primers, both at a 
final concentration of 300 µM. The protocol for amplification consisted of 25 cycles in the 
following setting: 95° C for 30 seconds, 60° C for 1 minute and 68° C for 10 minute. After 
amplification, the PCR product was incubated with 10 units of restriction enzyme Dpnl at 3 7° C 
for 30 minutes. The restriction enzyme Dpnl digests parental methylated and hemimethylated 
DNA, leaving only the DNA generated from the site-specific mutagenesis reaction. The plasmid 
was transformed into E. coli XL 10-Gold ultracompetent cells. The transformed cells were 
selected by plating onto LB plates containing 50 µg/ml kanamycin. Sequencing was done to 
confirm the presence of the two mutations. To allow expression of mutated TbLpn protein (His­
D EAD ), E. coli BL2 1 competent cells were transformed with the plasmid. The mutant His­
DEAD protein was expressed and purified as described for His-TbLpn. 
6. Trypanosoma brucei cellular fractionation 
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Log-phase PF T. brucei clone IsTaRl stock EA TRO 164 were harvested by 
centrifugation at 6,090 x g for 10 min at 4°C. The cells were washed twice using buffer A which 
contained 20 mM Hepes (pH 7.0), 150 mM sucrose, 20 mM KCL, 3 mM MgC}i, and 1 mM of 
DDT (added just befm:e use). The cells were then resuspended in Buffer A at a concentration of 
1X1010 cells/ml. NP-40 was added at a final concentration of 0.2%, and the cells were passed 
through a 26-gauge needle three times. This generated the whole cell extract. The whole cell 
extract was centrifuged at 13,000 X RPM for 10 minutes. The supernatant which represents the 
cytosolic extract was recovered. The pellet was resuspended in 1 ml of Buffer A and passes 
through a 26-gauge needle for 15 times. The cells were again centrifuged at 13,000 X RPM for 
10 minutes. The supernatant was discarded and the pellets rinsed with 0.5 ml of Buffer A. The 
pellets were resuspended in 0.5 ml of Buffer A. This constitutes the nuclear extract. 
7. Immunoprecipitation of native TbLpn 
As it was previously determined that TbLpn is localized in the cytosol, 
immunoprecipitation of TbLpn was performed using the cytosolic extract. Throughout the 
procedure, the immunoprecipitation buffer (IP buffer) consisted of Buffer A containing 10% NP-
40, 1 µg/ml of Pestatin A, 1 µg/ml of Leupeptin, and 1 mM PMSF. To obtain the TbLpn from 
cytosolic extract, the following immunoprecipitation procedure was used: In two 1.5 ml tubes (A 
and B) was placed 200 µl of cytosolic extract. To tube A was added 10 µl of purified anti-TbLpn 
antibodies and 90 µl of IP buffer. To tube B was added 100 µl IP buffer. The samples were 
rotated at 4°c for at least 12 h. At this point, 10 µl of Protein A-Sepharose (Sapharose, 
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Amersham) was added to each sample and rotated again for 1 hour at 4°C. The samples were 
centrifuged at 3,000 X g for 30 seconds and the supernatant carefully removed and labeled 
unbound A and unbound B (UA and UB). The pellets were washed 5 times, each time for 5 
minutes, with 1 ml IP buffer. Between each wash the samples were centrifuged and the 
supernatant discarded. The pellets were suspended in 40 µl of water and labeled bound A and 
bound B (BA and BB). 
8. Phosphatidic Acid Phosphatase Assays 
The Phosphatidic acid phosphatase assays was performed to determine the enzymatic 
activity of TbLpn. The samples included the wild type His-TbLpn, the mutant TbLpn (His­
DEAD), and native TbLpn obtained by immunoprecipitation from the cytosolic extract of 
Trypanosoma brucei. As mentioned earlier, Lipin protein family catalyzes dephosphorylation of 
Phosphatidic acid (PA) to diacylglycerol (DAG) which is used for the synthesis of 
phospholipids. The organic phosphate (Pi) is produced during the dephosphorylation process. 
The reaction proceeds with the presence of magnesium because the enzymatic activity of the 
lipin protein family depends on magnesium. The substrate used in the assay was 1,2-dioctanoyl­
sn-glycero-3-phosphate (DiC8PA) (Polar Lipids). It was resuspended in 1 ml of ddH20 to make a 
20 mM stock. The substrate was incubated at a final concentration of 0.4 mM with increasing 
amount of proteins in a total volume of 50 µl of reactants. The samples were incubated for 60 
minutes at 30° C. The enzymatic activity was stopped by adding 100µ1 of PiBlue reagent (turns 
green in reaction with phosphate produced). The samples were placed at room temperature for 30 
minute for color to develop, and the absorbance at 620 nm measured. 
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A standard curve allowing to determine the amount of phosphate produced during the 
phosphatidic acid phosphate assay was prepared. Different concentrations of lM phosphate 
standards were prepared as indicated below. The following concentrations were prepared. 
[PO/-] (µM) 1 M PO/- (µI) Water (µI) 
40 200 0 
32 160 40 
24 120 80 
16 80 120 
12  60 140 
8 40 1 60 
4 20 180 
0 0 200 
Fifty µl of each standard dilution was placed in 0.5-ml tubes in duplicate. To each 
duplicate was added 100 µl of PiBlue reagent. The color was allowed to develop for 60 minutes 
at room temperature, and the absorbance at 620 nm measured. 
CHAPTER 3 
RESULTS 
1. Expression and purification of His-TbLpn 
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In order to characterize the enzymatic activity of ThLpn in vitro, C-terminally his-tagged 
ThLpn was expressed in E. coli and purified by affinity chromatography using a Nickel resin. 
Following chromatography, the samples were prepared for analysis by SDS-PAGE. Ten µl of the 
flowthrough, 20 µl of the wash, as well as 20 µl of elution fractions 1,2,3,4,6,8 and 10 were 
mixed with the appropriate volume of 5X denaturation buffer (0.3 M Tris [pH 6.8], 40% 
glycerol, 10% SDS, 5% DTT, 0.05% bromophenol blue) and denatured at 100 °C for 5 min. The 
samples were then loaded onto a 7 .5% acrylamide SDS-PAGE separating gel (0.375 M Tris [pH 
8.8], 0.1% SDS) with a 4% acrylamide stacking gel (0. 125 M Tris [pH 6.8], 0 . 1% SDS). 
Following electrophoresis, the gel was stained with Coomassie Blue. The expression vector used 
for the expression of His-ThLpn encodes ThLpn fused in-frame to a His10/Smt3 domain, 
consisting of a His10 leader peptide (MGHHHHHHHHHHSSGHIEGRH) followed by the 98-
amino-acid Saccharomyces cerevisiae Smt3 protein (Smt3 is the yeast ortholog of the small 
ubiquitin-like modifier SUMO). The His1o/Smt3 domain adds 12.5 kDa to the size of the protein 
being expressed. As indicated earlier, the molecular weight of Trypanosoma brucei ThLpn is 
86.7kDa. As shown in Figure 17, a band of approximately 100 kDa was observed after 
purification over nickel resin. 
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To confirm the presence of a Histidine tag on the expressed protein, the sample were 
analyzed by Western hybridization using purified anti-His monoclonal antibodies. Figure 18 
clearly indicates the presence of a reactive protein at about 100 kDa. 
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Figure 1 7: Expression and purification of His-TbLpn. Recombinant H is-TbLpn was expressed in E.coli BL2 l and 
purified by affinity chromatography as described under Material and Methods. Molecular weight markers (M), 
n ickel column tlowthrough (FT), wash (W), and subsequent elution fractions 1 ,  2, 3, 4, 6, 8, and 1 0  were separated 
by SDS-PAGE on a 7.5% gel and stained with Coomassie Bri l l iant B lue. The 99.2-kDa fusion protein  is indicated 
with an arrow. 
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M (lilla) FT W 1 2 3 4 6 8 10 
Figure 1 8: The recombinant TbLpn protein contains a H istidine tail. Molecular weight markers (M), nickel column 
tlowthrough (FT), wash (W), and subsequent e lution fractions I ,  2, 3, 4, 6, 8, and 1 0  were separated by SOS-PAGE 
on a 7.5% gel and transferred onto a PVDF membrane. The presence of the H istidine tag was assessed by western 
hybridization using monoclonal anti His  antibodies. The 99.2-kDa fusion protein is indicated with an arrow. 
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2. Expression and purification of His-DEAD mutant 
C-terminally his-tagged mutant ThLpn (His-DEAD) was expressed in E. coli and purified 
by affinity chromatography using a Nickel resin following the same procedure as the wild type 
recombinant protein. Following chromatography, the samples were prepared for analysis by 
SDS-PAGE as described for wild type His-TbLpn. The analysis of the gel stained with 
Coomassie Blue reagent shows a band corresponding to the expected molecular weight of the 
ThLpn (� 100 kDa) (Figure 19). Western hybridization using purified anti-His monoclonal 
antibodies confirmed the presence of a Histidine tag (not shown) 
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Figure 1 9: Expression and purification of H is-DEAD. Recombinant H is-DEAD was expressed in E. coli BL2 l and 
purified by affinity chromatography as described under "Material and Methods". Molecular weight markers (M) and 
purified H is 's-DEAD were separated by SOS-PAGE on a 7.5% gel and stained with Coomassie Bril l iant Blue. The 
99.2-kDa fusion protein is indicated with an arrow. 
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In order to obtain His-TbLpn at a sufficient concentration for enzymatic assays, the 
elution fractions containing the highest amount of recombinant protein were concentrated by 
centrifugation. Following an approximate I O-fold concentration, the samples were prepared for 
analysis on a 7.5% polyacrylamide denaturing gel. Twenty µl of concentrated His-TbLpn was 
mixed with 5 µl of 5x SDS-PAGE buffer. The sample was denatured by boiling at 100 °C for 5 
minutes. In order to determine the concentration of purified His-TbLpn present in the 
concentrated sample, increasing amounts of purified anti-TbLpn IgGs were also loaded on the 
gel. Following electrophoresis, the gel was stained with Coomassie Blue. As shown in Figure 20, 
the intensity of the band corresponding to His-TbLpn was similar to the band obtained by 
loading 20 µI of anti-TbLpn IgGs. The IgGs used were at I µg/µl 
From this observation, we estimated the concentration of His-TbLpn to be 25 µg/µl. 
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Figure 20: Quantitation of H is-TbLpn. Purified recombinant TbLpn was concentrated as described under "Material 
and Methods. Molecu tar weight markers (M), H is-TbLpn (20 µ I), and increasing amounts of purified polyclonal 
anti-TbLpn antibodies (0.2, 0.5, I ,  2, and 3 µg) were separated by SOS-PAGE on a 7.5% gel and stained with 
Coomassie Bri l l iant Blue. The 99.2-kDa fusion protein is indicated with an arrow. The position of the anti-TbLpn 
heavy chains is marked with an asterisk (*). 
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3. Immunoprecipitation of native TbLpn 
As ThLpn has previously been shown to be localized to the cytosol, an 
immunoprecipitation was performed from T. brucei cytosolic extract in order to obtain pwified 
native ThLpn for enzymatic assays. Following incubation of the cytosolic extract with pwified 
polyclonal anti-TbLpn antibodies, Protein A coupled to Sepharose beads was added. The high 
affinity of Protein A for rabbit lgGs produces a large complex that can be easily visualized 
following centrifugation. Both unbound and bound fractions were analyzed by Western 
hybridization using polyclonal anti-TbLpn antibodies. As shown in Figure 2 1, a protein band 
with a molecular weight of approximately 87 kDa was pulled down by the anti-ThLpn antibodies 
(BA) but not dwing the mock reaction (BB). This clearly indicates a successful 
immunoprecipitation that will allow to pwify native TbLpn for subsequent enzymatic assays. 
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Figure 2 1 :  l mmunoprecipitation of TbLpn from T brucei cytosol. TbLpn was immunopurified from cytosolic 
extract using purified polyclonal anti-TbLpn antibodies as described under "Material and Methods". Molecular 
weight markers (M), unbound fraction (U), and bound fraction (B) were separated by SDS-PAGE on a 7.5% gel and 
transferred onto a PVDF membrane. The presence of TbLpn was determined western hybridization using polyclonal 
anti-TbLpn antibodies. The 86.7-kDa native TbLpn is indicated with an arrow. 
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4. In vitro phosphatidic acid phosphatase enzymatic activity of recombinant TbLpn 
Phosphatidic acid phosphatase assays were performed using the substrate 1,2-dioctanoyl­
sn-glycero-3-phosphate (DiC8 PA), Mg2+, and WT TbLpn enzyme for the baseline phosphatase 
activity, and the mutant TbLpn for the comparison of phosphatase activity. Varying amounts of 
enzyme were used, ranging from 125-625ng from the stock solutions collected. Both reactions 
were performed at 30 °C, and allowed to react for 30 minutes. Reactions were stopped using the 
PiBlue reagent and allowed to sit for 30 minute to develop color for absorbance studies. The 
PiBlue reagent binds to the phosphate released during the assay and produces a green color, The 
absorbance of each reaction was read at 620nm in a spectrophotometer and a nanodrop for more 
accurate results. The absorbances from both instruments were averaged and the amount of 
phosphate produced during the enzymatic assay determined from a previously obtained standard 
curve. To obtain the reaction rate for both wild type and mutant His-TbLpn, the concentration of 
phosphate obtained from the standard curve was divided by the total reaction time of 60 minutes 
to yield the rate of the reaction in nanomoles of phosphate/minute (Figure 22) 
Figure 22 clearly shows that TbLpn exhibits phosphatidate phosphatase activity in vitro, 
implying that TbLpn may play a role in the regulation of phospholipid synthesis due to its 
phosphatase activity as seen in the protein assays performed. By comparing the phosphatase 
activity levels in both the WT TbLpn and mutant TbLpn proteins, it is evident that the mutated 
TbLpn demonstrates significantly less phosphatase activity, implying that the two conserved 
residues of TbLpn are essential for this biochemical pathway and the regulation of phospholipid 
synthesis. Although the errors bars are large in Fig. 22, this implies that the protein assays are 
extremely sensitive and vary depending on extremely controlled conditions. Even with the 
varying data, it is still evident that the mutated TbLpn protein is significantly hindered in 
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phosphate activity. The presence of other E. coli proteins in either sample is negated due to the 
replication of processes for protein purification for the WT and mutant TbLpn, implying that 
even if other proteins are in the sample and could contribute to the phosphate activity, the only 
difference in both assays is the TbLpn protein itself and is the main contributor to the activity 
difference. 
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Figure 22: Recombinant TbLpn displays phosphatidic acid phosphatase act1v1ty. The enzymatic act1v 1ty was 
measured by the release of phosphate from 1 ,2-d ioctanoyl-sn-glycero-3-phosphate (DiC8 PA). The substrate was 
incubated with increasing amounts of either H is-TbLpn (black bars) or H is-DEAD (white bars) recombinant 
proteins. The amount of phosphate released was measured using Pi  Blue reagent and recording the absorbance at 620 
nm. 
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5. Phosphatidic acid phosphatase enzymatic activity of native TbLpn 
In an attempt to measure the enzymatic activity of native TbLpn, the protein was 
immunoprecipitated using purified polyclonal anti-TbLpn as described under "Material and 
Methods". The immune complex was then incubated with Protein A bound to Sepharose beads 
and the bound material obtained by centrifugation. Increasing amounts of immunopurified 
TbLpn was incubated with the substrate 1,2-dioctanoyl-sn-glycero-3-phosphate (DiC8 PA) in the 
presence of Mg2+. Reactions were performed at 30 °C for 60 minutes. Following addition of 
PiBlue reagent and further incubation for 30 minutes, the absorbance was measured. 
The results did not show progressive increases of released Pi with increasing amount of 
the enzyme (data not shown). Factors that might explain these unexpected results will be 
discussed in the next section. 
CHAPTER 4 
DISCUSSION 
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The first part of this project was to successfully express and purify both the wild type and 
mutant TbLpn from E. coli. The expression of His-tagged TbLpn from E. coli BL21 cells was 
induced with IPTG for 17 hours at 17 °C. It has previously been determined that the low 
temperature prevents the production of inclusion bodies and facilitates the solubility of the 
recombinant protein. Following expression, the cells were lyzed and the His-tagged proteins 
purified by chromatography affinity using nickel resin. The presence of His-TbLpn and his­
DEAD was then ascertained by SDS-P AGE followed by Coomassie blue staining and western 
hybridization. Several attempts were made with unsuccessful expression of the protein. One of 
the conditions which were changed several times was the cell lysis procedure. For the first 
attempt, the cells were lysed followed by centrifugation at 14,000 X RPM for 10 minutes. During 
the second attempt, the cells were centrifuged at 3,500 X RPM for 30 minutes. In the last attempt 
the cells were lysed and centrifuged at 17 ,000 X g for 15 minutes. These last conditions resulted 
in the highest amount of proteins recovered. It can be concluded that centrifugation at higher 
speed and at adequate time is necessary for the cell lysate to retain the bulk of the proteins 
without the cell debris. 
The other important parameters which were changed several times had to do with the 
conditions used during chromatography. During the first three attempts, which all resulted in 
very low protein yield, the nickel affinity chromatography was performed at room temperature, 
and the flowthrough, wash, and elution fractions collected on ice. For the last attempt, the whole 
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process was performed at 4° C. Under these conditions, we were able to obtain a significant 
protein yield as well as enzymatically active TbLpn. This reinforces the fact that enzymes should 
be exposed to conditions that keep them active. The conditions at 4 ° C seem favorable for 
enzymatic activity of TbLpn. The enzyme likely may have been denatured or inactivated when 
the chromatography was performed at room temperature, even though fractions were collected 
on ice. Although the above mentioned conditions were changed for the successful expression and 
purification of TbLpn, the samples had to be concentrated in order to obtain a sufficient TbLpn 
concentration for enzymatic assays. Briefly the ten elution fractions were combined and 
concentrated as described to a final volume of 250 µl. This corresponds to approximately a 40-
fold concentration. 
In addition to assessing the enzymatic activity of recombinant TbLpn, we also wanted to 
determine the in vivo activity of TbLpn. In order to obtain sufficient amount of native TbLpn for 
phosphatidic acidi phosphatase enzymatic assays, TbLpn was immunoprecipitated from a 
cytosolic extract obtained from procyclic form Trypanosoma brucei. This procedure included 
incubating the extract with anti-TbLpn antibodies, rotating the samples for a precise period of 
time, allowing for binding of the antibodies to the protein, and separation of the bound and 
unbound fractions. The amount of the cytosolic extract used for immunoprecipitation was one of 
the determining factors for successful analysis of TbLpn by western hybridization. In the first 
two trials, 100 µl of the cytosolic extract was used. The expected band corresponding to the size 
of native TbLpn (� 86 kDa) was not observed on any of the western hybridization membranes. 
We later began to lmmunoprecipitate TbLpn from 200 µl of cytosolic extract. Theses samples 
lead to sufficient amounts of immunoprecitated TbLpn. Another important condition for 
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successful recovery of TbLpn was the incubation time allowed for the proteins to interact with 
the anti-TbLpn antibodies. The samples that allowed optimal recovery were rotated at 4 °C over 
the weekend. It appears that the long period of rotation was important for binding of the 
antibodies to the protein. 
The main objective of this research project as mentioned above was to determine the 
enzymatic activity of. TbLpn. The members of lipin protein family have conserved domains 
which have been identified in TbLpn. Lipin proteins catalyze the dephosphorylation of 
phosphatidic acid (PA) to diacylglycerol (DAG). During the dephosphorylation process, 
inorganic phosphate is produced. The catalytic activity of the lipin protein family depends on 
magnesium. Since TbLpn share all the characteristics of the lipin protein family including the 
enzymatic residues of asphatic acid in the conserved domain, it was hypothesized that it should 
have similar enzymatic activity. The enzymatic motif of TbLpn was identified as the two aspartic 
acid residues at the C-LIP end. The wild type samples for TbLpn were reacted in all the reagents 
and conditions necessary for the enzymatic activity. The production of inorganic phosphate 
which turned the PiBlue reagent green and was confirmed by reading the absorbance for the 
samples at 620 nm confirmed the enzymatic activify of the TbLpn as had been expected. This 
clearly demonstrates that TbLpn is a member of lipin protein family and is able to carry out 
dephosphorylation of phosphatidic acid as expected. 
The results for the mutant TbLpn samples were equally exciting. The mutant lipin whose 
the two conserved aspartic acid residues within the C-LIP domain were changed to alanines 
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demonstrated significantly less phosphatase activity, implying that the two conserved residues of 
TbLpn are essential for this biochemical pathway and the regulation of phospholipid synthesis. 
When TbLpn was immunoprecipitated from T. brucei cytosolic extract and used in 
enzymatic assays, no inorganic phosphate could be detected, indicating that the extract did not 
demonstrate any phosphatidic acid phosphatase enzymatic activity. There are possible reasons to 
explain the unexpected results. Insufficient amount of inorganic phosphate might have been 
produced and could not be detected by reading absorbance at 620 nm. It would be interesting to 
concentrate the sample following immunoprecipitation to increase the amount of enzyme for the 
catalytic activity. Another possibility to explain the lack of detectable activity resides in the 
attachment of the antibodies to the enzyme. The attached antibodies might inhibit the enzymatic 
activity of the protein or block some catalytic sites, resulting in production of no or undetectable 
phosphate. To circumvent this issue, immunoprecipitated TbLpn could be eluted from the 
antibodies by incubation with a competing TbLpn peptide. 
The life cycle of T. brucei involves an intermediate host, the tsetse fly, as well as a 
definitive mammalian host. Examination of the TriTrypDB database devoted to kinetoplastid 
genome analysis indicates that the TbLpn mRNA is present at similar levels in procyclic and 
bloodstream form T. brucei. However, as the control of gene expression is performed at the post­
transcriptional level in T. brucei, it remains possible that the TbLpn protein levels are 
significantly different in procyclic and bloodstream forms. The relative abundance of TbLpn will 
be determined by western hybridization of procyclic and bloodstream form cellular extracts. 
TbLpn might be significantly more abundant in the bloodstream than the procyclic form. In 
addition, post-translational modifications such as phosphorylation and arginine methylation may 
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function in inhibiting TbLpn enzymatic activity while in the tsetse fly or, conversely, may serve 
to activate the enzyme once the parasite is passed to a mammalian host. 
Specifically, lipin plays an important role in the production of certain phospholipids and 
the production of fatty acids. In particular, phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) which are products of the Kennedy pathway for lipid 
biosynthesis. These particular phospholipids, constitute not only the composition of the cell 
membrane in T. brucei. In addition, PE is a precursor of glycosylphosphatidylinositol (GPI) 
synthesis. In yeast, lipin is utilized in the initial reaction by dephosphorylating phosphatidate. 
The product of this would be used in the expression of surface protein, which changes between 
fly form and mammalian form trypanosome and also contributes to T. brucei high antigenic 
variation. 
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